Skip to main
OMDA
OMDA logo

OMDA Stock Forecast & Price Target

OMDA Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Omada Health Inc exhibits a promising growth trajectory, supported by a projected revenue increase of over 35% in FY25 and a strong move towards adjusted EBITDA breakeven. The company's margin expansion, driven by AI integration that enhances efficiency and member engagement, further strengthens its financial position, particularly as it capitalizes on its role as a companion solution for GLP-1 medication users. Additionally, the rise in enrollments due to targeted outreach, along with expanding partnerships with prominent pharmacy benefit managers such as Express Scripts and CVS Caremark, underscores Omada's potential to gain market share and deliver significant value amidst increasing corporate interest in GLP-1 treatments.

Bears say

Omada Health Inc has experienced a reduction in adjusted operating expenses as a percentage of revenue from FY’22 to FY’24, dropping from 121.1% to 80.5%, indicating improving operational efficiency. However, despite this progress, forecasts suggest that average revenue per user (ARPU) will remain relatively flat, raising concerns about revenue growth potential in subsequent years. Additionally, potential declines in demand for Omada’s GLP-1 CareTracks, linked to safety issues and evolving market dynamics, combined with the risk of deteriorating relationships with key partners, could significantly hinder the company's financial performance and long-term scalability.

OMDA has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Omada Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Omada Health Inc (OMDA) Forecast

Analysts have given OMDA a Buy based on their latest research and market trends.

According to 8 analysts, OMDA has a Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Omada Health Inc (OMDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.